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Abstract: The relationship between liver enzymes and clustered components of metabolic 
syndrome (MetS) is explored and the predictive power of γ-glutamyl transferase (GGT) for 
the diagnosis of MetS in an adult population in Beijing is investigated. A total of 10,553 
adults aged 20–65 years who underwent health examinations at Beijing Tongren Hospital 
in 2012 were enrolled in the study. Multivariate logistic regression analysis is conducted  
to determine the associations between the levels of various liver enzymes and clustered 
components of MetS. A receiver operating characteristic analysis is used to determine the 
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optimal cut-off value of GGT for the diagnosis of MetS. A high level of GGT is found to 
be positively associated with clustered components of MetS in both men and women after 
adjusting for age, body mass index (BMI), history of alcoholic fatty liver, and the presence 
of taking anti-hypertensive, anti-dyslipidemic, and anti-diabetic drugs. Among all components 
of MetS, GGT is more predictive of triglyceride, and BMI. The area-under-the-curve values 
of GGT for discriminating MetS from normal metabolic status in men and women are 0.73 
and 0.80, respectively. The optimal cut-off value of GGT for men is 31.50 U/L, demonstrating 
a sensitivity of 74.00% and specificity of 62.00%. For women, it is 19.50 U/L (sensitivity 
76.00% and specificity 70.00%). GGT is therefore recommended as a useful diagnostic marker 
for MetS, because the test is inexpensive, highly sensitive, and frequently encountered in 
clinical practice. 
Keywords: liver enzymes; metabolic syndrome; gamma-glutamyl transferase; diagnosis 
 
1. Introduction 
γ-Glutamyl transferase (GGT) is independently associated with several pathological conditions, 
including cardiovascular disease (CVD) [1,2], diabetes [3–5], and metabolic syndrome (MetS) [6–9]. 
The enzyme is involved in glutathione metabolism and plays critical roles in antioxidant defense, detoxification, 
and inflammation processes. Moreover, it has recently been found to be involved in many physiological 
disorders, such as Parkinson’s disease and diabetes [10]. Also oxidative stress is suggested to be involved 
in the onset of several obesity-related disorders such as hypertension, dyslipidemia, type-2 diabetes 
mellitus and MetS [11]. MetS is a cluster of risk factors that include abdominal obesity, 
hyperglycaemia, raised blood pressure (BP), low high-density lipoprotein (HDL-C) and high 
triglyceride (TG). The prevalence of MetS is growing rapidly and is associated with an increased risk 
of nonalcoholic fatty liver disease, diabetes, CVD, and total mortality [12,13], thus the identification of 
biomarkers for MetS is of pivotal importance.  
Based on the available biochemical and clinical evidence, an association between high levels of 
GGT and MetS has been hypothesized. Many large-scale prospective studies have reported that high 
levels of GGT, even when within the normal range [14–17], is a strong and independent predictor of 
increased risk of stroke, cardiovascular mortality, and a number of MetS components [4,18–21]. These 
findings suggest the possibility that a high level of GGT might reflect the development of MetS and is, 
in general, independent of the effects of other metabolic risk factors. Other liver enzymes, including 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) 
were also reported to be positively related to an increased risk of MetS and related disorders [22–26]. 
Many references have suggested that liver enzymes are emerging as biomarkers of MetS and its clustering 
components in adolescents. However, it is not fully understood which liver enzyme are better indicators 
of MetS or clustering of its components. 
Several studies have investigated the association between GGT and MetS, as well as the optimal 
cut-off values for this biomarker [26,27]. Other studies have explored the association between GGT 
and MetS in Chinese populations in particular [21,28]. However, inferences about the optimal cut-off 
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values of GGT for the diagnosis of MetS have not been reported. The present study was designed to 
explore the relationship between GGT and clustered components of MetS. Moreover, it was designed 
to determine the optimal cut-off values for GGT that could be used to discriminate MetS from normal 
metabolic conditions. 
2. Methods  
2.1. Study Population 
This cross-sectional study was designed to enroll a population of adults from Beijing who attended 
health examinations in 2012 at Beijing Tongren Hospital. In total, 13,613 subjects were enrolled.  
We excluded 3,060 patients with a history of CVD, myocardial infarction, cerebral infarction, gastric 
cancer, coronary artery bypass surgery, coronary stenting surgery, gastrectomy, and/or liver cirrhosis. 
Thus, a total of 10,553 adults living in Beijing (4,764 men and 5,789 women) were included in the 
final analysis. This study was approved by the ethics committee of Capital Medical University in 
Beijing (approval number: 2013SY26). All participants provided informed written consent. 
2.2. Measurements 
Information about medication use was gathered by trained medical staff during a standardized 
interview. Subjects who reported taking anti-hypertensive, anti-dyslipidemic or anti-diabetic drugs were 
considered to have elevated BP, elevated TG, reduced HDL-C or elevated fasting plasma glucose (FPG). 
The participants underwent routine physical examinations that included the measurement of height, 
weight, BP, and overnight fasting blood sampling. Weight and height were measured without shoes, and 
body mass index (BMI) was calculated as weight (kg) divided by squared height (m). BP was measured 
on the right arm of subjects seated and at rest for at least 5-min by a trained nurse. During the 30 min 
preceding the measurements, the subjects were required to refrain from smoking or consuming caffeine. 
Three systolic and diastolic blood pressures were recorded, with an interval of at least 1 min between 
readings, and the average of the last two measurements were used for data analysis. 
Blood samples were obtained from antecubital vein in the morning after an overnight fasting period 
and placed in tubes containing EDTA. HDL-C, TG, FPG, GGT, ALT, AST, and ALP were measured 
enzymatically using a chemistry analyzer (Beckman LX 20, Pasadena, CA, USA) at the central 
laboratory of the hospital. Serum GGT was assayed using the standard method recommended by the 
International Federation for Clinical Chemistry. That is, L-γ-glutamyl-3-carboxy-4-nitroanilide was 
used as substrate at a temperature of 37 °C with a normal reference range of 11–50 U/L for men, and 
7–32 U/L for women [29]. The normal laboratory reference ranges for ALT, AST, and ALP are 0–40, 
0–40, and 15–112 U/L, respectively. The sensitivity of the assay is 2 U/L. All analyses were performed in 
accordance with the manufacturer’s recommendations. The intra and inter-assay coefficients of 
variation for all laboratory tests were under 5%. 
2.3. Definition of MetS 
MetS was diagnosed if the subjects had three or more risk determinants according to the Joint 
Interim Statement criteria [30]. However, in this study, waist circumference (WC) was not measured 
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because of limited health check-up site, and BMI was taken as a substitute for the component of 
obesity [31]. The determinants were as follows: 
1. Obesity: BMI ≥ 28 kg/m²;  
2. Elevated TG (drug treatment for elevated TG is an alternate indicator) ≥ 150 mg/dL  
(1.7 mmol/L);  
3. Reduced HDL-C (drug treatment for reduced HDL-C is an alternate indicator) < 40 mg/dL  
(1.0 mmol/L) in males, <50 mg/dL (1.3 mmol/L) in females;  
4. Elevated BP (anti-hypertensive drug treatment in a patient with a history of hypertension is 
an alternate indicator) systolic ≥ 130 mm Hg and/or diastolic ≥ 85 mm Hg; and, 
5. Elevated FPG (drug treatment of elevated glucose is an alternate indicator) ≥ 100 mg/dL. 
2.4. Data Analysis 
Data was analyzed using the SAS software (version 9.2, SAS Institute, Cary, NC, USA), and p < 0.05 
was considered as significant. To compare the differences between groups, Student’s t test or Wilcoxon 
rank sum test was used for continuous variables, and χ2 test or Fisher’s exact test was used for categorical 
variables. The odds ratios (ORs) and 95% confidence intervals (CIs) were assessed using multivariate 
logistic regression analysis to determine the associations between four liver enzymes and clustered 
components of MetS after adjusting for age, BMI, alcoholic fatty liver history, and the presence of 
prescriptive drug taking (anti-hypertensive, anti-dyslipidemic, and anti-diabetic drugs). The four liver 
enzymes levels were respectively classified into four groups using the 25th, 50th, and 75th percentiles 
as cut-points. Receiver operating characteristic (ROC) curve was used to determine the optimal cut-off 
values for these four liver enzymes in terms of their sensitivity and specificity for diagnosing MetS. 
The area under the curve (AUC) was calculated and 95% CI was estimated.  
3. Results 
3.1. Prevalence of MetS and its Components 
The sex-specific prevalence of MetS and its components are described in Table 1 and Figure 1. 
Overall, the prevalence of MetS among all subjects was 13.43%, with 19.75% of men and 8.22% of 
women diagnosed with MetS. It was shown that men have a higher prevalence of MetS, elevated BP, 
elevated TG, elevated BMI, and elevated FPG levels, whereas women demonstrated a slightly higher 
prevalence of reduced HDL-C. 
3.2. Basic Characteristics and Hematological Parameters 
The basic characteristics and hematological parameters of all subjects are shown in Table 2.  
In addition to the levels of five MetS components and four liver enzymes, the prevalence of history of 
alcoholic fatty liver, and taking anti-hypertensive, anti-dyslipidemic, and anti-diabetic drugs were 
significantly higher in the MetS group than the non-MetS group for both men and women. 
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Table 1. Prevalence of MetS and its components by gender. 
Sex Total 
MetS 
Elevated  
BP 
Elevated  
TG 
Reduced 
HDL-C 
Elevated BMI 
Elevated  
FPG 
n % n % n % n % n % n % 
Men 4,764 941 19.75 1,702 35.73 1,666 34.97 1,214 25.48 794 16.67 1,371 28.78 
Women 5,789 476 8.22 849 14.67 769 13.28 1,488 25.70 342 5.91 1,059 18.29 
Total 10,553 1,417 13.43 2,551 24.17 2,435 23.07 2,702 25.60 1,136 10.76 2,430 23.03 
n: The number of cases with MetS, or abnormal components; %: The prevalence of cases with MetS or abnormal components among 
male, female, or total subjects. Abbreviations: MetS = metabolic syndrome; BP = blood pressure; TG = triglyceride; HDL-C = high-
density lipoprotein cholesterol; BMI = body mass index; FPG = fasting plasma glucose. 
Figure 1. Prevalence of MetS and its components by sex. 
 
Abbreviations: MetS = metabolic syndrome; BP = blood pressure; TG = triglyceride; HDL-C = high-density lipoprotein cholesterol; 
BMI = body mass index; FPG = fasting plasma glucose. 
Table 2. Basic characteristics and hematological parameters by gender. 
Variables 
Men 
p Value 
Women 
p Value 
MetS non-MetS MetS non-MetS 
N 941 3,823 - 476 5,313 - 
Age (year) 44 (35–53) 38 (31–49) <0.0001 a 50 (43–57) 40 (30–49) <0.0001 a 
SBP (mmHg) 130 ± 15 118 ± 14 <0.0001 b 128 ± 17 111 ± 13 <0.0001 b 
DBP (mmHg) 84 ± 10 75 ± 10 <0.0001 b 81 ± 10 70 ± 9 <0.0001 b 
HDL-C (mmol/L) 0.97 ± 0.22 1.26 ± 0.29 <0.0001 b 1.13 ± 0.21 1.58 ± 0.34 <0.0001 b 
TG (mmol/L) 2.97 ± 2.21 1.46 ± 1.18 <0.0001 b 2.34 ± 1.26 0.96 ± 0.60 <0.0001 b 
FPG (mmol/L) 6.34 ± 1.79 5.36 ± 1.04 <0.0001 b 6.40 ± 1.81 5.17 ± 0.74 <0.0001 b 
BMI (kg/m2) 28.21 ± 3.25 24.39 ± 4.02 <0.0001 b 27.41 ± 3.71 22.05 ± 2.93 <0.0001 b 
GGT (U/L) 52.09 ± 31.74 34.01 ± 22.97 <0.0001 b 33.53 ± 23.17 19.92 ± 13.51 <0.0001 b 
ALT (U/L) 45.58 ± 32.17 30.95 ± 30.22 <0.0001 b 31.84 ± 19.28 20.38 ± 19.59 <0.0001 b 
AST (U/L) 37.50 ± 14.52 31.05 ± 19.26 <0.0001 b 34.64 ± 13.25 27.54 ± 11.98 <0.0001 b 
ALP (U/L) 65.68 ± 15.87 62.35 ± 15.10 <0.0001 b 65.18 ± 18.31 53.43 ± 16.19 <0.0001 b 
History of alcoholic fatty liver, n (%) 27 (2.87) 41 (1.07) <0.0001c 8 (1.68) 11 (0.21) <0.0001 c 
Anti-hypertensive drugs, n (%) 256 (27.21) 346 (9.05) <0.0001 c 174 (36.55) 337 (6.34) <0.0001 c 
Anti-dyslipidemic drugs, n (%) 205 (21.79) 206 (5.39) <0.0001 c 90 (18.91) 272 (5.12) <0.0001 c 
Anti-diabetic drugs, n (%) 80 (8.50) 93 (2.56) <0.0001 c 49 (10.29) 92 (1.73) <0.0001 c 
Abbreviations: MetS = metabolic syndrome; SBP = systolic blood pressure; DBP = diastolic blood pressure; HDL-C = high-density 
lipoprotein cholesterol; TG = triglyceride; FPG = fasting plasma glucose; BMI = body mass index; GGT = gamma-glutamyl transferase; 
ALT = alanine aminotransferase; AST = aspartate aminotransferase; ALP = alkaline phosphatase. a Determined using the rank-sum test;  
b Determined using t test; c Determined using χ2 test. 
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3.3. Association between Liver Enzymes and MetS, as well as its Components 
The associations between four liver enzymes and MetS, as well as its components, were explored 
using multivariate logistic regression model after adjusting for age, BMI, history of alcoholic fatty 
liver, and the presence of taking anti-hypertensive, anti-dyslipidemic, and anti-diabetic drugs. 
The associations between the four liver enzymes and MetS are shown in Table 3. Compared with 
the first quartile group, the adjusted OR of GGT for indicating MetS increased from 1.40 (95% CI: 
1.09–1.96) to 3.50 (95% CI: 2.50–4.91) for men and from 1.80 (95% CI: 1.04–3.10) to 5.61 (95% CI: 
3.41–9.23) for women. ALT was significantly associated with MetS in quartile 3 and 4 for men, and in 
quartile 4 for women. AST was associated with MetS in quartile 4 for both men and women. ALP was 
associated with MetS in quartiles 3 and 4 for women, and in quartile 4 for men.  
Table 3. Factors associated with MetS by gender. 
 Q1 Q2 Q3 Q4 
Men 
GGT (U/L) ≤20 21–29 30–43 ≥44 
Cases/subjects at risk 64/1,178 151/1,213 261/1,167 465/1,206 
OR (95% CI: lower–upper) 1.00 1.40 (1.09–1.96) 2.09 (1.50–2.91) 3.50 (2.50–4.91) 
ALT (U/L) ≤19 20–27 28–38 ≥39 
Cases/subjects at risk 98/1,191 176/1,201 242/1,188 425/1,184 
OR (95% CI: lower–upper) 1.00 1.23 (0.90–1.66) 1.43 (1.05–1.95) 1.81 (1.28–2.55) 
AST (U/L) ≤24 25–30 31–36 ≥37 
Cases/subjects at risk 129/1,214 188/1,294 222/1,145 402/1,111 
OR (95% CI: lower–upper) 1.00 1.09 (0.82–1.45) 1.07 (0.80–1.43) 1.62 (1.19–2.20) 
ALP (U/L) ≤52 53–61 62–71 ≥72 
Cases/subjects at risk 198/1,288 217/1,106 244/1,202 282/1,168 
OR (95% CI: lower–upper) 1.00 1.24 (0.96–1.61) 1.29 (0.99–1.66) 1.48 (1.16–1.90) 
Women 
GGT (U/L) ≤13 14–17 18–22 ≥23 
Cases/subjects at risk 22/1,843 44/1,386 100/1,151 310/1,409 
OR (95% CI: lower–upper) 1.00 1.80 (1.04–3.10) 3.49 (2.11–5.78) 5.61 (3.41–9.23) 
ALT (U/L) ≤13 14–18 19–23 ≥24 
Cases/subjects at risk 27/1,480 64/1,624 98/1,248 287/1,437 
OR (95% CI: lower–upper) 1.00 1.30 (0.79–2.13) 1.44 (0.88–2.35) 1.95 (1.19–3.21) 
AST (U/L) ≤22 23–26 27–31 ≥32 
Cases/subjects at risk 36/1,451 80/1,494 110/1,434 250/1,410 
OR (95% CI: lower–upper) 1.00 1.62 (1.04–2.54) 1.33 (0.85–2.07) 2.01 (1.29–3.15) 
ALP (U/L) ≤42 43–51 52–63 ≥64 
Cases/subjects at risk 43/1,556 66/1,352 141/1,519 226/1,362 
Abbreviations: MetS = metabolic syndrome; GGT = gamma-glutamyl transferase; ALT = alanine aminotransferase; AST 
= aspartate aminotransferase; ALP = alkaline phosphatase; OR = odds ratio; CI = confidence interval. 
The associations between the four liver enzymes and elevated BP are shown in Table 4.  
The adjusted OR of GGT for indicating elevated BP increased from 1.24 (95% CI: 1.02–1.51) to 2.18  
(95% CI: 1.76–2.70) for men, while GGT was positively associated with elevated BP in quartile 3 for 
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women. Risk of elevated BP increased with an increase in ALT level for men, and ALT was significantly 
associated with elevated BP in quartile 3 and 4 for women. No positive association was found between 
AST and elevated BP for men and women. ALP was positively associated with elevated BP in quartile 3 
and 4 for women, but no association was found for men. 
Table 4. Factors associated with elevated BP by gender. 
 Q1 Q2 Q3 Q4 
Men 
GGT (U/L) ≤20 21–29 30–43 ≥44 
n (%) 272/1,178 374/1,213 453/1,167 603/1,206 
OR (95% CI: lower–upper) 1.00 1.24 (1.02–1.51) 1.48 (1.21–1.81) 2.18 (1.76–2.70) 
ALT (U/L) ≤19 20–27 28–38 ≥39 
n (%) 304/1,191 410/1,201 464/1,188 524/1,184 
OR (95% CI: lower–upper) 1.00 1.26 (1.05–1.53) 1.41 (1.16–1.72) 1.45 (1.16–1.80) 
AST (U/L) ≤24 25–30 31–36 ≥37 
n (%) 340/1,214 463/1,294 408/1,145 491/1,111 
OR (95% CI: lower–upper) 1.00 1.20 (0.99–1.44) 0.97 (0.80–1.18) 1.04 (0.83–1.30) 
ALP (U/L) ≤52 53–61 62–71 ≥72 
n (%) 437/1,288 381/1,106 402/1,202 482/1,168 
OR (95% CI: lower–upper) 1.00 0.94 (0.78–1.12) 0.86 (0.72–1.03) 1.16 (0.97–1.38) 
Women 
GGT (U/L) ≤13 14–17 18–22 ≥23 
Cases/subjects at risk 142/1,843 155/1,386 210/1,151 342/1,409 
OR (95% CI: lower–upper) 1.00 1.15 (0.89–1.48) 1.46 (1.13–1.88) 1.28 (0.98–1.66) 
ALT (U/L) ≤13 14–18 19–23 ≥24 
Cases/subjects at risk 111/1,480 187/1,624 202/1,248 349/1,437 
OR (95% CI: lower–upper) 1.00 1.26 (0.97–1.63) 1.40 (1.07–1.83) 1.68 (1.27–2.21) 
AST (U/L) ≤22 23–26 27–31 ≥32 
Cases/subjects at risk 134/1,451 172/1,494 233/1,434 310/1,410 
OR (95% CI: lower–upper) 1.00 0.95 (0.73–1.23) 1.12 (0.86–1.44) 1.15 (0.87–1.52) 
ALP (U/L) ≤42 43–51 52–63 ≥64 
Cases/subjects at risk 109/1,556 136/1,352 254/1,519 350/1,362 
OR (95% CI: lower–upper) 1.00 1.26 (0.95–1.65) 1.79 (1.39–2.31) 1.87 (1.43–2.45) 
Abbreviations: BP = blood pressure; GGT = gamma-glutamyl transferase; ALT = alanine aminotransferase; AST = 
aspartate aminotransferase; ALP = alkaline phosphatase; OR = odds ratio; CI = confidence interval. 
The associations between the four liver enzymes and elevated TG are shown in Table 5.  
The adjusted OR of GGT for predicting elevated TG increased from 2.03 (95% CI: 1.63–2.55) to 4.79 
(95% CI: 3.78–6.08) for men, and from 1.73 (95% CI: 1.22–2.47) to 5.15 (95% CI: 3.70–7.16) for 
women. Risk for elevated TG increased with the increase in ALT level for men, and ALT was 
significantly associated with elevated TG in quartile 3 and 4 for women. AST was significantly associated 
with elevated TG in quartile 3 and 4 for men, and in quartile 4 for women. Positive associations were 
found between ALP and elevated TG for men and women. 
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Table 5. Factors associated with elevated TG by gender. 
 Q1 Q2 Q3 Q4 
Men 
GGT (U/L) ≤20 21–29 30–43 ≥44 
Cases/subjects at risk 212/1,178 272/1,213 328/1,167 402/1,206 
OR (95% CI: lower–upper) 1.00 2.03 (1.63–2.55) 3.10 (2.47–3.89) 4.79 (3.78–6.08) 
ALT (U/L) ≤19 20–27 28–38 ≥39 
Cases/subjects at risk 160/1,191 283/1,201 297/1,188 444/1,184 
OR (95% CI: lower–upper) 1.00 1.38 (1.12–1.71) 1.56 (1.26–1.94) 1.74 (1.36–2.23) 
AST (U/L) ≤24 25–30 31–36 ≥37 
Cases/subjects at risk 272/1,214 264/1,294 298/1,145 380/1,111 
OR (95% CI: lower–upper) 1.00 1.21 (0.99–1.47) 1.44 (1.17–1.77) 1.75 (1.39–2.20) 
ALP (U/L) ≤52 53–61 62–71 ≥72 
Cases/subjects at risk 241/1,288 289/1,106 322/1,202 362/1,168 
OR (95% CI: lower–upper) 1.00 1.29 (1.06–1.56) 1.31 (1.09–1.52) 1.40 (1.16–1.69) 
Women 
GGT (U/L) ≤13 14–17 18–22 ≥23 
Cases/subjects at risk 302/1,843 299/1,386 334/1,151 553/1,409 
OR (95% CI: lower–upper) 1.00 1.73 (1.22–2.47) 3.68 (2.65–5.11) 5.15 (3.70–7.16) 
ALT (U/L) ≤13 14–18 19–23 ≥24 
Cases/subjects at risk 280/1,480 358/1,624 334/1,248 516/1,437 
OR (95% CI: lower–upper) 1.00 1.39 (0.99–1.94) 1.62 (1.15–2.27) 1.81 (1.27–2.57) 
AST (U/L) ≤22 23–26 27–31 ≥32 
Cases/subjects at risk 307/1,451 350/1,494 361/1,434 470/1,410 
OR (95% CI: lower–upper) 1.00 1.24 (0.91–1.69) 1.22 (0.90–1.65) 1.68 (1.24–2.30) 
ALP (U/L) ≤42 43–51 52–63 ≥64 
Cases/subjects at risk 271/1,556 331/1,352 428/1,519 458/1,362 
OR (95% CI: lower–upper) 1.00 1.45 (1.06–1.99) 1.72 (1.29–2.31) 2.06 (1.53–2.78) 
Abbreviations: TG = triglyceride; GGT = gamma-glutamyl transferase; ALT = alanine aminotransferase; AST = aspartate 
aminotransferase; ALP = alkaline phosphatase; OR = odds ratio; CI = confidence interval. 
The associations between the four liver enzymes and reduced HDL-C are shown in Table 6.  
The adjusted OR of GGT for predicting reduced HDL-C increased from 1.30 (95% CI: 1.08–1.55) to 
2.38 (95% CI: 1.98–2.85) for women, but no positive association was found for men. ALT was 
positively associated with reduced HDL-C for men, but no association was shown for women. The 
association between AST and reduced HDL-C was not found for men and women. ALP was significantly 
associated with reduced HDL-C for both men and women. 
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Table 6. Factors associated with reduced HDL-C by gender. 
 Q1 Q2 Q3 Q4 
Men 
GGT (U/L) ≤20 21–29 30–43 ≥44 
Cases/subjects at risk 212/1,178 272/1,213 328/1,167 402/1,206 
OR (95% CI: lower–upper) 1.00 1.04 (0.84–1.28) 1.14 (0.92–1.43) 1.20 (0.95–1.51) 
ALT (U/L) ≤19 20–27 28–38 ≥39 
Cases/subjects at risk 191/1,191 283/1,201 297/1,188 444/1,184 
OR (95% CI: lower–upper) 1.00 1.54 (1.25–1.91) 1.61 (1.29–2.00) 2.45 (1.92–3.11) 
AST (U/L) ≤24 25–30 31–36 ≥37 
Cases/subjects at risk 272/1,214 264/1,294 298/1,145 380/1,111 
OR (95% CI: lower–upper) 1.00 0.73 (0.60–0.89) 0.81 (0.66–1.00) 0.84 (0.66–1.06) 
ALP (U/L) ≤52 53–61 62–71 ≥72 
Cases/subjects at risk 241/1,288 289/1,106 322/1,202 362/1,168 
OR (95% CI: lower–upper) 1.00 1.50 (1.23–1.84) 1.53 (1.26–1.86) 1.78 (1.46–2.16) 
Women 
GGT (U/L) ≤13 14–17 18–22 ≥23 
Cases/subjects at risk 302/1,843 299/1,386 334/1,151 553/1,409 
OR (95% CI: lower–upper) 1.00 1.30 (1.08–1.55) 1.78 (1.48–2.14) 2.38 (1.98–2.85) 
ALT (U/L) ≤13 14–18 19–23 ≥24 
Cases/subjects at risk 280/1,480 358/1,624 334/1,248 516/1,437 
OR (95% CI: lower–upper) 1.00 1.05 (0.87–1.26) 1.13 (0.92–1.38) 1.22 (0.98–1.53) 
AST (U/L) ≤22 23–26 27–31 ≥32 
Cases/subjects at risk 307/1,451 350/1,494 361/1,434 470/1,410 
OR (95% CI: lower–upper) 1.00 0.99 (0.83–1.20) 0.90 (0.74–1.09) 1.01 (0.82–1.24) 
ALP (U/L) ≤42 43–51 52–63 ≥64 
Cases/subjects at risk 271/1,556 331/1,352 428/1,519 458/1,362 
OR (95% CI: lower–upper) 1.00 1.39 (1.15–1.67) 1.53 (1.28–1.83) 1.68 (1.38–2.05) 
Abbreviations: HDL-C = high-density lipoprotein cholesterol; GGT = gamma-glutamyl transferase; ALT = alanine 
aminotransferase; AST = aspartate aminotransferase; ALP = alkaline phosphatase; OR = odds ratio; CI = confidence interval. 
The associations between the four liver enzymes and elevated FPG are shown in Table 7. The adjusted 
OR of GGT increased from 1.46 (95% CI: 1.16–1.84) to 2.38 (95% CI: 1.90–2.99) for women,  
and positive association between GGT and elevated FPG were shown in quartile 3 and 4 for men. ALT 
was significantly associated with elevated FPG in quartile 3 and 4 for women, but significant 
association was not found for women. AST was positively correlated with elevated FPG in quartile 4 
for men, and in quartile 2 and 4 for women. ALP was significantly correlated with elevated FPG in 
quartile 3 and 4 for women, but no positive association was found for men. 
Table 7. Factors associated with elevated FPG by gender. 
 Q1 Q2 Q3 Q4 
Men 
GGT (U/L) ≤20 21–29 30–43 ≥44 
Cases/subjects at risk 210/1,178 280/1,213 393/1,167 488/1,206 
OR (95% CI: lower–upper) 1.00 1.15 (0.92–1.44) 1.75 (1.41–2.19) 2.23 (1.77–2.80) 
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Table 7. Cont. 
 Q1 Q2 Q3 Q4 
Men 
ALT (U/L) ≤19 20–27 28–38 ≥39 
Cases/subjects at risk 275/1,191 346/1,201 345/1,188 405/1,184 
OR (95% CI: lower–upper) 1.00 1.04 (0.84–1.29) 0.95 (0.75–1.19) 1.10 (0.84–1.44) 
AST (U/L) ≤24 25–30 31–36 ≥37 
Cases/subjects at risk 277/1,214 329/1,294 330/1,145 435/1,111 
OR (95% CI: lower–upper) 1.00 1.08 (0.88–1.33) 1.13 (0.91–1.40) 1.56 (1.25–1.95) 
ALP (U/L) ≤52 53–61 62–71 ≥72 
Cases/subjects at risk 356/1,288 314/1,106 332/1,202 369/1,168 
OR (95% CI: lower–upper) 1.00 0.95 (0.77–1.16) 0.92 (0.75–1.12) 0.95 (0.78–1.15) 
Women     
GGT (U/L) ≤13 14–17 18–22 ≥23 
Cases/subjects at risk 160/1,843 193/1,386 243/1,151 463/1,409 
OR (95% CI: lower–upper) 1.00 1.46 (1.16–1.84) 1.90 (1.51–2.39) 2.38 (1.90–2.99) 
ALT (U/L) ≤13 14–18 19–23 ≥24 
Cases/subjects at risk 147/1,480 210/1,624 251/1,248 451/1,437 
OR (95% CI: lower–upper) 1.00 1.24 (0.95–1.62) 1.35 (1.02–1.79) 1.55 (1.15–2.09) 
AST (U/L) ≤22 23–26 27–31 ≥32 
Cases/subjects at risk 154/1,451 231/1,494 250/1,434 424/1,410 
OR (95% CI: lower–upper) 1.00 1.32 (1.05–1.68) 1.17 (0.93–1.49) 1.86 (1.48–2.35) 
ALP (U/L) ≤42 43–51 52–63 ≥64 
Cases/subjects at risk 159/1,556 181/1,352 316/1,519 403/1,362 
OR (95% CI: lower–upper) 1.00 1.25 (0.95–1.65) 1.78 (1.38–2.30) 1.85 (1.41–2.42) 
The associations between the four liver enzymes and elevated BMI are shown in Table 8. The adjusted 
OR of GGT for indicating elevated BMI increased from 2.65 (95% CI: 1.86–3.78) to 4.97 (95% CI: 
3.47–7.11) for men, and from 2.15 (95% CI: 1.26–3.67) to 5.88 (95% CI: 3.56–9.70) for women. Risk 
for elevated BMI increased with the increase in ALT level for men, and ALT was significantly 
associated with elevated BMI in quartile 3 and 4 for women. No significant association was found 
between AST, ALP and elevated BMI for men and women.  
Table 8. Factors associated with elevated BMI by gender. 
 Q1 Q2 Q3 Q4 
Men 
GGT (U/L) ≤20 21–29 30–43 ≥44 
Cases/subjects at risk 45/1,178 151/1,213 228/1,167 370/1,206 
OR (95% CI: lower–upper) 1.00 2.65 (1.86–3.78) 3.28 (2.30–4.68) 4.97 (3.47–7.11) 
ALT (U/L) ≤19 20–27 28–38 ≥39 
Cases/subjects at risk 72/1,191 141/1,201 191/1,188 390/1,184 
OR (95% CI: lower–upper) 1.00 1.49 (1.09–2.03) 1.68 (1.23–2.29) 3.17 (2.33–4.32) 
AST (U/L) ≤24 25–30 31–36 ≥37 
Cases/subjects at risk 116/1,214 157/1,294 203/1,145 318/1,111 
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Table 8. Cont. 
 Q1 Q2 Q3 Q4 
Men 
OR (95% CI: lower–upper) 1.00 0.86 (0.65–1.13) 0.96 (0.73–1.28) 1.00 (0.74–1.35) 
ALP (U/L) ≤52 53–61 62–71 ≥72 
Cases/subjects at risk 188/1,288 194/1,106 215/1,202 197/1,168 
OR (95% CI: lower–upper) 1.00 1.20 (0.94–1.52) 1.11 (0.88–1.41) 0.85 (0.67–1.09) 
Women 
GGT (U/L) ≤13 14–17 18–22 ≥23 
Cases/subjects at risk 21/1,843 42/1,386 71/1,151 208/1,409 
OR (95% CI: lower–upper) 1.00 2.15 (1.26–3.67) 3.32 (1.99–5.55) 5.88 (3.56–9.70) 
ALT (U/L) ≤13 14–18 19–23 ≥24 
Cases/subjects at risk 22/1,480 50/1,624 80/1,248 190/1,437 
OR (95% CI: lower–upper) 1.00 1.54 (0.92–2.58) 2.26 (1.36–3.75) 2.87 (1.74–4.72) 
AST (U/L) ≤22 23–26 27–31 ≥32 
Cases/subjects at risk 36/1,451 52/1,494 97/1,434 157/1,410 
OR (95% CI: lower–upper) 1.00 0.94 (0.60–1.48) 1.28 (0.83–1.96) 1.26 (0.81–1.96) 
ALP (U/L) ≤42 43–51 52–63 ≥64 
Cases/subjects at risk 36/1,556 58/1,352 96/1,519 152/1,362 
OR (95% CI: lower–upper) 1.00 1.38 (0.89–2.15) 1.56 (0.83–2.37) 1.75 (0.95–2.68) 
Abbreviations: BMI = body mass index; GGT = gamma-glutamyl transferase; ALT = alanine aminotransferase;  
AST = aspartate aminotransferase; ALP = alkaline phosphatase; OR = odds ratio; CI = confidence interval. 
Among all MetS components, GGT is more predictive of elevated TG and BMI according to 
Tables 4–8. 
3.4. ROC Analysis of Various Liver Enzymes for the Diagnosis of MetS 
The ROC analysis of GGT in comparison with the other liver enzymes is shown in Table 9 and 
Figure 2. The AUC was 0.73 (95% CI: 0.71–0.75) for GGT, 0.69 (95% CI: 0.67–0.71) for ALT, 0.67 
(95% CI: 0.65–0.69) for AST, and 0.56 (95% CI: 0.54–0.58) for ALP for men. As for women, the AUC 
was 0.80 (95% CI: 0.78–0.82) for GGT, 0.76 (95% CI: 0.74–0.79) for ALT, 0.71 (95% CI: 0.69–0.74) for 
AST, and 0.70 (95% CI: 0.68–0.73) for ALP. 
Table 9. ROC analysis of liver enzymes for the diagnosis of MetS. 
 Variables Area 
95% CI 
Lower Upper 
Men 
 GGT (U/L) 0.73 0.71 0.75 
 ALT (U/L) 0.69 0.67 0.71 
 AST (U/L) 0.67 0.65 0.69 
 ALP (U/L) 0.56 0.54 0.58 
Women 
 GGT (U/L) 0.80 0.78 0.82 
 ALT (U/L) 0.76 0.74 0.79 
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Table 9. Cont. 
 Variables Area 
95% CI 
Lower Upper 
Women 
 AST (U/L) 0.71 0.69 0.74 
 ALP (U/L) 0.70 0.68 0.73 
Abbreviations: MetS = metabolic syndrome; GGT = gamma-glutamyl transferase; ALT = alanine 
aminotransferase; AST = aspartate aminotransferase; ALP = alkaline phosphatase; ROC = receiver operating 
characteristics; CI = confidence interval. 
Figure 2. ROC analysis of GGT, ALT, AST, and ALP for the diagnosis of MetS. 
 
Abbreviations: MetS = metabolic syndrome; GGT = gamma-glutamyl transferase; ALT = alanine 
aminotransferase; AST = aspartate aminotransferase; ALP = alkaline phosphatase; ROC = receiver 
operating characteristic; AUC = area under the curve. 
The sensitivity, specificity, and GGT cut-off values for the diagnosis of MetS are presented in Table 10. 
According to the ROC curve analysis, the optimal cut-off value for GGT that can be used to diagnosis 
for MetS is 31.50 U/L, demonstrating a sensitivity of 74.00% and specificity of 62.00% for men, and 
the optimal cut-off value was 19.50 U/L with a sensitivity of 76.00% and specificity of 70.00% for women. 
Table 10. Sensitivity and specificity values of specific GGT levels for the diagnosis of MetS. 
 GGT (U/L) Sensitivity Specificity 
Men    
 29.50 0.77 0.57 
 30.50 0.76 0.60 
 31.50 0.74 0.62 
 32.50 0.71 0.64 
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Table 10. Cont. 
 GGT (U/L) Sensitivity Specificity 
Women    
 17.50 0.86 0.60 
 18.50 0.81 0.65 
 19.50 0.76 0.70 
 20.50 0.71 0.74 
 21.50 0.68 0.77 
Abbreviation: GGT = gamma-glutamyl transferase; MetS = metabolic syndrome. 
4. Discussion 
The main result of the present study is that serum GGT can be used as an important predictor of 
MetS for adults aged 25–65 years living in Beijing. This study mainly evaluated serum liver enzyme 
levels, including GGT, ALT, AST, and ALP, as risk markers for MetS. Moreover, the optimal cut-off 
value of GGT for discriminating MetS from normal status was investigated. The majority of similar 
studies demonstrated the high power of GGT for diagnosing MetS. Moreover, to the best of our 
knowledge, this is the first study to investigate the optimal GGT cut-off value for the diagnosis of MetS 
in a population from Mainland China. 
As in the findings reported by Hwang et al. [21], when samples in the present study were divided 
into quartiles according to GGT level, high GGT was significantly correlated with a higher prevalence 
of MetS after adjusting for age, BMI, history of alcoholic fatty liver, and medication use. Similarly, 
Rantala et al. investigated the association between GGT and MetS, reporting a highly significant 
relationship between GGT and MetS even after adjusting for age, BMI, and alcohol consumption [32]. 
A 4-year cohort study of 3,698 Korean male workers indicated that elevated GGT could be a sensitive 
marker of MetS [8]. In another study, serum GGT was associated with the components of MetS [27,33]. 
Serum GGT is an important predictor of MetS in both men and women without MetS at baseline [34,35]. 
In a study on Korean adults, the prevalence of MetS, the number of MetS components, and insulin 
resistance increased as the quartile of serum GGT increased [36]. 
Modest increase in GGT may be an early marker of cellular oxidative stress via mediation of 
extracellular glutathione transport into cells of organ systems, or as a mediator of low-grade systemic 
inflammation and explains the strong association of serum GGT with many cardiometabolic risk 
factors and diseases [37]. Oxidative stress, assessed by circulating prostaglandin F2α levels, is recognized 
to be related to obesity [11,38]. The documented predictability of metabolic disorders of MetS, hypertension, 
and diabetes by GGT activity suggests that, as a reflection of oxidative stress, elevated GGT levels are 
actively involved in the pathogenesis of these disorders [5]. 
In the present study, ALT, AST, and ALP were also found to be positively associated with MetS 
and its components for both men and women. Several emerging studies reported that patients with altered 
hematological ALT, AST, and ALP status are at high risk of developing MetS and its components [39–41]. 
However, the associations between ALT, AST, ALP, and MetS were weaker than GGT in this study. 
Also, GGT was more predictive of elevated TG and BMI, compared with the other three MetS components. 
According to our results, GGT demonstrates high sensitivity and a partial good specificity for 
discriminating MetS from non-MetS. New cut-off values of 31.5 and 19.5 U/L GGT were determined 
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for the diagnosis of abnormal MetS conditions in men and women, respectively. Kasapoglu et al. 
reported the optimum cut-off values of 26.5 and 20.5 U/L GGT for diagnosing MetS in a population of 
Turkish men and women, respectively [42]. Gholamreza derived optimum cut-off values of 20.5 and 
16.5 U/L GGT for men and women, respectively, in an Iranian population [29]. The Fifth Korea 
National Health and Nutrition Examination Survey reported a lower cut-off value of 14 U/L in a Korea 
population [22], but approximately similar sensitivity and specificity values for the discriminative 
power of GGT (77.0% and 62.0%, respectively). 
There are two limitations to the present study. The first limitation is the lack of WC measurements 
as an indicator for central obesity. However, BMI was used as a substitute [31], and it has been shown 
that the two measures of BMI and WC are closely correlated [43]. Another study has indicated that 
most individuals with an abnormal BMI also have an abnormal WC. Both indices of excess adiposity 
are positively associated with SBP, FPG, and TG, and inversely associated with HDL-C [44]. Secondly, 
information about alcohol consumption was not available, and the multivariate model was adjusted for 
history of alcoholic fatty liver. However, these lifestyle variables will be included in further studies. 
5. Conclusions  
The study confirms the association between GGT and clustered components of MetS. Moreover, 
our study highlights that, among the four plasma markers of liver injury that were evaluated, GGT is 
the most strongly associated with MetS in this adult population in Beijing. Moreover, the study 
indicates that GGT is a sensitive but moderately specific marker for the early diagnosis of MetS in 
adults living in Beijing. GGT is therefore recommended as a useful diagnostic marker of MetS, because 
the test is inexpensive, highly sensitive, and frequently measured in clinical practice. 
Acknowledgments 
The study was supported by the Major Project of Natural Science Fund of Beijing (serial number: 
7131002), Key Projects in the National Science & Technology Pillar Program in the Twelfth Five-year 
Plan Period of China (2011BAI08B01), the Program of Natural Science Fund of China (serial number: 
81373099), the Program of Natural Science Fund of Beijing (serial number: 4112015), and the Project 
for Beijing Municipal Natural Science Foundation (7122016). The authors would also like to thank the 
medical personnel of Beijing Tongren Hospital who collected the data used in this study. 
Conflicts of Interest 
The authors declare no conflicts of interest. 
References 
1. Kim, K.M.; Kim, B.T.; Lee, D.J.; Park, S.B.; Joo, N.S.; Kim, K.N. Serum gamma-glutamyltransferase 
as a risk factor for general cardiovascular disease prediction in Koreans. J. Investig. Med. 2012, 
60, 1199–1203. 
Int. J. Environ. Res. Public Health 2013, 10 5537 
 
 
2. Hurjui, D.M.; Nita, O.; Graur, L.I.; Mihalache, L.; Popescu, D.S.; Hutanasu, I.C.; Ungureanu, D.; 
Graur, M. Non-alcoholic fatty liver disease is associated with cardiovascular risk factors of 
metabolic syndrome. Rev. Med. Chir. Soc. Med. Nat. Iasi. 2012, 116, 692–699. 
3. Schneider, A.L.; Lazo, M.; Ndumele, C.E.; Pankow, J.S.; Coresh, J.; Clark, J.M.; Selvin, E. Liver 
enzymes, race, gender and diabetes risk: The Atherosclerosis Risk in Communities (ARIC) Study. 
Diabet. Med. 2013, 30, 926–933. 
4. Nguyen, Q.M.; Srinivasan, S.R.; Xu, J.H.; Chen, W.; Hassig, S.; Rice, J.; Berenson, G.S. Elevated 
liver function enzymes are related to the development of prediabetes and type 2 diabetes in 
younger adults: The Bogalusa Heart Study. Diabetes Care 2011, 34, 2603–2607. 
5. Onat, A.; Can, G.; Ornek, E.; Cicek, G.; Ayhan, E.; Dogan, Y. Serum gamma-glutamyltransferase: 
Independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary 
disease. Obesity (Silver Spring) 2012, 20, 842–848. 
6. Lee, J.H.; Um, M.H.; Park, Y.K. The association of metabolic syndrome and serum gamma-glutamyl 
transpeptidase: A 4-year cohort study of 3,698 korean male workers. Clin. Nutr. Res. 2013, 2, 67–75. 
7. Bian, A.L.; Wang, X.F. Relationship between serum gamma-glutamyltransferase and the risk of 
metabolic syndrome. Zhonghua Liu Xing Bing Xue Za Zhi 2011, 32, 625–628. 
8. Oh, H.J.; Kim, T.H.; Sohn, Y.W.; Kim, Y.S.; Oh, Y.R.; Cho, E.Y.; Shim, S.Y.; Shin, S.R.; Han, A.L.; 
Yoon, S.J.; et al. Association of serum alanine aminotransferase and gamma-glutamyltransferase 
levels within the reference range with metabolic syndrome and nonalcoholic fatty liver disease. 
Korean J. Hepatol. 2011, 17, 27–36. 
9. Bozbas, H.; Yildirir, A.; Karacaglar, E.; Demir, O.; Ulus, T.; Eroglu, S.; Aydinalp, A.; Ozin, B.; 
Muderrisoglu, H. Increased serum gamma-glutamyltransferase activity in patients with metabolic 
syndrome. Turk Kardiyol. Dern. Ars. 2011, 39, 122–128. 
10. Castellano, I.; Merlino, A. γ-Glutamyltranspeptidases: Sequence, structure, biochemical properties, 
and biotechnological applications. Cell. Mol. Life Sci. 2012, 69, 3381–3394. 
11. Abete, I.; Goyenechea, E.; Zualet, M.A.; Martinez, J.A. Obesity and metabolic syndrome: 
Potential benefit from specific nutritional components. Nutr. Metab. Cardiovasc. Dis. 2011, 
21(Suppl. 2), B1–B15. 
12. McNeill, A.M.; Rosamond, W.D.; Girman, C.J.; Golden, S.H.; Schmidt, M.I.; East, H.E.; 
Ballantyne, C.M.; Heiss, G. The metabolic syndrome and 11-year risk of incident cardiovascular 
disease in the atherosclerosis risk in communities study. Diabetes Care 2005, 28, 385–390. 
13. Guize, L.; Thomas, F.; Pannier, B.; Bean, K.; Jego, B.; Benetos, A. All-cause mortality associated 
with specific combinations of the metabolic syndrome according to recent definitions. Diabetes 
Care 2007, 30, 2381–2387. 
14. Shimizu, Y.; Imano, H.; Ohira, T.; Kitamura, A.; Kiyama, M.; Okada, T.; Sato, S.; Shimamoto, T.; 
Yamagishi, K.; Tanigawa, T.; et al. Gamma-Glutamyltranspeptidase and incident stroke among 
Japanese men and women: The Circulatory Risk in Communities Study (CIRCS). Stroke 2010, 
41, 385–388. 
15. Fraser, A.; Harris, R.; Sattar, N.; Ebrahim, S.; Smith, G.D.; Lawlor, D.A. Gamma-glutamyltransferase 
is associated with incident vascular events independently of alcohol intake: Analysis of the British 
women’s heart and health study and meta-analysis. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 
2729–2735. 
Int. J. Environ. Res. Public Health 2013, 10 5538 
 
 
16. Ruttmann, E.; Brant, L.J.; Concin, H.; Diem, G.; Rapp, K.; Ulmer, H. Gamma-glutamyltransferase 
as a risk factor for cardiovascular disease mortality: An epidemiological investigation in a cohort 
of 163,944 Austrian adults. Circulation 2005, 112, 2130–2137. 
17. Liu, C.F.; Zhou, W.N.; Fang, N.Y. Gamma-glutamyltransferase levels and risk of metabolic 
syndrome: A meta-analysis of prospective cohort studies. Int. J. Clin. Pract. 2012, 66, 692–698. 
18. Hanley, A.J.; Williams, K.; Festa, A.; Wagenknecht, L.E.; D’Agostino, R.B., Jr.; Kempf, J.; 
Zinman, B.; Haffner, S.M. Elevations in markers of liver injury and risk of type 2 diabetes: The 
insulin resistance atherosclerosis study. Diabetes 2004, 53, 2623–2632. 
19. Lee, D.H.; Jacobs, D.R., Jr.; Gross, M.; Steffes, M. Serum gamma-glutamyltransferase was differently 
associated with microalbuminuria by status of hypertension or diabetes: The Coronary Artery 
Risk Development in Young Adults (CARDIA) Study. Clin. Chem. 2005, 51, 1185–1191. 
20. Xu, Y.; Bi, Y.F.; Xu, M.; Huang, Y.; Lu, W.Y.; Gu, Y.F.; Ning, G.; Li, X.Y. Cross-sectional and 
longitudinal association of serum alanine aminotransaminase and gamma-glutamyltransferase with 
metabolic syndrome in middle-aged and elderly Chinese people. J. Diabetes 2011, 3, 38–47. 
21. Hwang, A.C.; Lin, Y.C.; Liu, P.T.; Kao, Y.M.; Chen, J.D. Synergistic effect of gamma 
glutamyltransferase and obesity on metabolic syndrome, independent of hepatic steatosis. Ann. 
Epidemiol. 2012, 22, 876–880. 
22. Lee, K.; Yang, J.H. Which liver enzymes are better indicators of metabolic syndrome in 
adolescents: The Fifth Korea National Health and Nutrition Examination Survey, 2010. Metab. 
Syndr. Relat. Disord. 2013, 11, 229–235. 
23. Goessling, W.; Massaro, J.M.; Vasan, R.S.; D’Agostino, R.B., Sr.; Ellison, R.C.; Fox, C.S. 
Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular 
disease. Gastroenterology 2008, 135, 1935–1944.e1, doi: 10.1053/j.gastro.2008.09.018. 
24. Hanley, A.J.; Williams, K.; Festa, A.; Wagenknecht, L.E.; D’Agostino, R.B., Jr.; Haffner, S.M. 
Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis 
study. Diabetes 2005, 54, 3140–3147. 
25. Patel, D.A.; Srinivasan, S.R.; Xu, J.H.; Chen, W.; Berenson, G.S. Persistent elevation of liver 
function enzymes within the reference range is associated with increased cardiovascular risk in 
young adults: The Bogalusa Heart Study. Metabolism 2007, 56, 792–798. 
26. Kim, M.K.; Baek, K.H.; Kang, M.I.; Park, S.E.; Rhee, E.J.; Park, C.Y.; Lee, W.Y.; Oh, K.W. 
Serum alkaline phosphatase, body composition, and risk of metabolic syndrome in middle-aged 
Korean. Endocr. J. 2013, 60, 321–328. 
27. Yousefzadeh, G.; Shokoohi, M.; Yeganeh, M.; Najafipour, H. Role of gamma-glutamyl 
transferase (GGT) in diagnosis of impaired glucose tolerance and metabolic syndrome: A prospective 
cohort research from the Kerman Coronary Artery Disease Risk Study (KERCADRS). Diabetes 
Metab. Syndr. 2012, 6, 190–194. 
28. Kong, A.P.; Choi, K.C.; Ho, C.S.; Chan, M.H.; Ozaki, R.; Chan, C.W.; Chan, J.C. Associations of 
uric acid and gamma-glutamyltransferase (GGT) with obesity and components of metabolic 
syndrome in children and adolescents. Pediatr. Obes. 2012, 8, 351–357. 
29. Targher, G. Elevated serum gamma-glutamyltransferase activity is associated with increased risk 
of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and  
cancer—A narrative review. Clin. Chem. Lab. Med. 2010, 48, 147–157. 
Int. J. Environ. Res. Public Health 2013, 10 5539 
 
 
30. Alberti, K.G.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.;  
Fruchart, J.C.; James, W.P.; Loria, C.M.; Smith, S.C., Jr. Harmonizing the metabolic syndrome:  
A joint interim statement of the International Diabetes Federation Task Force on Epidemiology 
and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World 
Heart Federation; International Atherosclerosis Society; and International Association for the 
Study of Obesity. Circulation 2009, 120, 1640–1645. 
31. Chen, C.; Lu, F.C. The guidelines for prevention and control of overweight and obesity in Chinese 
adults. Biomed. Environ. Sci. 2004, 17, 1–36. 
32. Rantala, A.O.; Lilja, M.; Kauma, H.; Savolainen, M.J.; Reunanen, A.; Kesaniemi, Y.A.  
Gamma-glutamyl transpeptidase and the metabolic syndrome. J. Intern. Med. 2000, 248, 230–238. 
33. Sakugawa, H.; Nakayoshi, T.; Kobashigawa, K.; Nakasone, H.; Kawakami, Y.; Yamashiro, T.; 
Maeshiro, T.; Tomimori, K.; Miyagi, S.; Kinjo, F.; et al. Metabolic syndrome is directly associated 
with gamma glutamyl transpeptidase elevation in Japanese women. World J. Gastroenterol. 2004, 
10, 1052–1055. 
34. Andre, P.; Balkau, B.; Vol, S.; Charles, M.A.; Eschwege, E. Gamma-glutamyltransferase activity 
and development of the metabolic syndrome (International Diabetes Federation Definition) in 
middle-aged men and women: Data from the Epidemiological Study on the Insulin Resistance 
Syndrome (DESIR) cohort. Diabetes Care 2007, 30, 2355–2361. 
35. Suh, B.S. The association between serum gamma-glutamyltransferase within normal levels and 
metabolic syndrome in office workers: A 4-year follow-up study. Korean J. Fam. Med. 2012, 33, 
51–58. 
36. Kang, Y.H.; Min, H.K.; Son, S.M.; Kim, I.J.; Kim, Y.K. The association of serum gamma 
glutamyltransferase with components of the metabolic syndrome in the Korean adults. Diabetes 
Res. Clin. Pract. 2007, 77, 306–313. 
37. Nakanishi, N.; Suzuki, K.; Tatara, K. Serum gamma-glutamyltransferase and risk of metabolic 
syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004, 27, 1427–1432. 
38. Lim, J.S.; Yang, J.H.; Chun, B.Y.; Kam, S.; Jacobs, D.R., Jr.; Lee, D.H. Is serum  
gamma-glutamyltransferase inversely associated with serum antioxidants as a marker of oxidative 
stress? Free Radic. Biol. Med. 2004, 37, 1018–1023. 
39. Wu, X.Y.; Hu, C.L.; Wan, Y.H.; Su, P.Y.; Xing, C.; Qi, X.Y.; Tao, F.B. Higher waist-to-height 
ratio and waist circumference are predictive of metabolic syndrome and elevated serum alanine 
aminotransferase in adolescents and young adults in mainland China. Public Health 2012, 126, 
135–142. 
40. Oda, E.; Kawai, R.; Watanabe, K.; Sukumaran, V. Prevalence of metabolic syndrome increases 
with the increase in blood levels of gamma glutamyltransferase and alanine aminotransferase in 
Japanese men and women. Intern. Med. 2009, 48, 1343–1350. 
41. Zhang, H.; Ding, Y.; Li, Q.; Sun, J.; He, S.; Feng, X.; Zhao, Y.; Zhou, X.; Cai, Y.; Wang, C.; et al. 
Relationship between serum aminotransferase levels and metabolic disorders in northern China. 
Iran. J. Public Health 2012, 41, 15–26. 
42. Kasapoglu, B.; Turkay, C.; Bayram, Y.; Koca, C. Role of GGT in diagnosis of metabolic 
syndrome: A clinic-based cross-sectional survey. Indian J. Med. Res. 2010, 132, 56–61. 
Int. J. Environ. Res. Public Health 2013, 10 5540 
 
 
43. Freiberg, M.S.; Pencina, M.J.; D’Agostino, R.B.; Lanier, K.; Wilson, P.W.; Vasan, R.S. BMI vs. 
waist circumference for identifying vascular risk. Obesity (Silver Spring) 2008, 16, 463–469. 
44. Abbasi, F.; Blasey, C.; Reaven, G.M. Cardiometabolic risk factors and obesity: Does it matter whether 
BMI or waist circumference is the index of obesity? Am. J. Clin. Nutr. 2013, 98, 637–640. 
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
